Topic: venture capital (VC)
TP Therapeutics netted $80 million and a new CEO as it looks to move its lead candidate in drug-resistant tumors into phase 2 early next year.
Seeking further returns from Taiho Ventures, Taiho Pharma just decided to multiply its investment pool sixfold to $300 million.
Cardialen raised $17 million to fund its low-energy defibrillator that aims to avoid the negative effects of high-energy shocks.
Gotham Therapeutics has raised $54 million to advance small-molecule inhibitors of mRNA-modifying proteins as far as clinical proof of concept.
New York biotech Rgenix has raised $40 million to advance drugs for solid tumors and gastrointestinal cancers.
After a big third quarter, the total for the first nine months of the year is $6.3 billion, putting the region on course to clear the $8 billion bar.
Blackstone plans to fund R&D programs that have outgrown the means of traditional venture capital firms.
This year’s class of Fierce 15 landed during a banner year for venture capital investment in biotech. We asked them if they thought the trend would continue or if the bubble would burst.
The addition of €90 million since the first close in July means Forbion has pulled in almost twice as much money as it managed for its third fund.
The British biotech sector enjoyed a big third quarter, with more than £460 million in VC cash flowing into the bank accounts of U.K. companies.